2024

Recommendations on imaging in the context of Alzheimer’s disease modifying therapies from the CCNA imaging workgroup

Authors:

Duchesne, S.,* Collins, D. L.,* Barlow, L., Bartha, R.,* Black, S.,* Chertkow, H.,* Dadar, M.,* Joshi, M., Rosa-Neto, P.,* Soucy, J. P., & Smith, E. E.*

Journal:

Canadian Journal of Neurological Sciences

Abstract

Background: Disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (Aβ) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as Aβ-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.

Methods: The Workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI, and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles, and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.

Results: The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions; tailored monitoring protocols based on DMTs’ safety and efficacy profiles; consistent monitoring regardless of perceived treatment efficacy; and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20 to 30 minutes was deemed feasible; specific sequences are suggested.

Conclusion: The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial, and logistical capacity to deliver additional MRI and PET scans require careful planning.

Share

CCNA - CCNV white logo

Receive the
latest news

Stay updated with the latest research developments from CCNA-CCNV. Our news section provides insights into cutting-edge studies, advancements in dementia care, and key findings in brain health research.

Illustration of elderly people on a park bench